A5010090426- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Gastrointestinal Tumor Research and Treatment
- Metastasis and carcinoma case studies
- Cancer Treatment and Pharmacology
- Esophageal Cancer Research and Treatment
- Lung Cancer Treatments and Mutations
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Neuroendocrine Tumor Research Advances
- HER2/EGFR in Cancer Research
- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Esophageal and GI Pathology
- Genetic factors in colorectal cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Helicobacter pylori-related gastroenterology studies
- Lung Cancer Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Intraperitoneal and Appendiceal Malignancies
- Cancer Diagnosis and Treatment
- Cancer therapeutics and mechanisms
National Cancer Center Hospital East
2016-2025
St. Marianna University School of Medicine
2011-2025
University of Tokyo Hospital
2022-2025
Shiga University of Medical Science Hospital
2022-2025
The University of Tokyo
2021-2025
Tokyo University of Science
2021-2025
Tokyo National Hospital
2015-2024
Tokyo Medical University Hospital
2021-2024
National Cancer Center
2008-2023
Tokyo Medical University
2022-2023
Japanese mortality due to colorectal cancer is on the rise, surpassing 49,000 in 2015. Many new treatment methods have been developed during recent decades. The Society for Cancer of Colon and Rectum Guidelines 2016 (JSCCR 2016) were prepared show standard strategies cancer, eliminate disparities among institutions terms treatment, unnecessary insufficient deepen mutual understanding between health-care professionals patients by making these available general public. These consensus reached...
Purpose The present phase III study was designed to investigate the noninferiority of S-1 alone and superiority gemcitabine plus compared with respect overall survival. Patients Methods participants were chemotherapy-naive patients locally advanced or metastatic pancreatic cancer. randomly assigned receive only (1,000 mg/m 2 on days 1, 8, 15 a 28-day cycle), (80, 100, 120 mg/d according body-surface area 1 through 28 42-day (gemcitabine 1,000 8 60, 80, 100 14 21-day cycle). Results In total...
Colorectal cancer is a major cause of death in Japan, where it accounts for the largest number deaths from malignant neoplasms among women and third men. Many new methods treatment have been developed during recent decades. The Japanese Society Cancer Colon Rectum Guidelines 2014 colorectal (JSCCR 2014) prepared as standard strategies cancer, to eliminate disparities institutions, unnecessary insufficient treatment, deepen mutual understanding health-care professionals patients by making...
This phase III study compared treatment with weekly paclitaxel and biweekly irinotecan in patients advanced gastric cancer refractory to fluoropyrimidine plus platinum.Patients were randomly assigned receive either (80 mg/m(2) on days 1, 8, 15, every 4 weeks) or (150 1 weeks). Primary end point was overall survival (OS), secondary points progression-free (PFS), response rate, adverse events, proportion of who received third-line chemotherapy.Of 223 patients, 219 eligible for analysis. Median...
BackgroundThere currently are no internationally recognised treatment guidelines for patients with advanced gastric cancer/gastro-oesophageal junction cancer (GC/GEJC) in whom two prior lines of therapy have failed. The randomised, phase III JAVELIN Gastric 300 trial compared avelumab versus physician's choice chemotherapy as third-line GC/GEJC.Patients and methodsPatients unresectable, recurrent, locally advanced, or metastatic GC/GEJC were recruited at 147 sites globally. All randomised to...
To compare fluorouracil (FU) alone with FU plus cisplatin (FP) and uracil tegafur mitomycin (UFTM) for patients advanced gastric cancer in a prospective, randomized, controlled trial.A total of 280 were randomly allocated analyzed survival, response, toxicity. The survival curves compared between groups by log-rank test on an intent-to-treat basis.At the interim analysis, UFTM arm showed significantly inferior higher incidences hematologic toxic effects than did control alone, registration...
PURPOSE: To investigate the efficacy and feasibility of concurrent chemoradiotherapy for locally advanced carcinoma esophagus. PATIENTS AND METHODS: Fifty-four patients with clinically T4 and/or M1 lymph node (LYM) squamous cell esophagus were enrolled. Patients received protracted infusion fluorouracil 400 mg/m 2 /24 hours on days 1 to 5 8 12, 2-hour cisplatin 40 8, radiation therapy at a dose 30 Gy in 15 fractions over 3 weeks. Filgrastim was prophylactically administered 35 patients. This...
For one-piece resection the conventional technique of endoscopic mucosal (EMR) is limited to gastric tumors 10 mm or less in size. In this retrospective study, we investigated efficacy and complications associated with a new EMR method, using an insulated-tip diathermic knife (IT-EMR).In total 41 patients were resected IT-EMR.One-piece rates 82% (14/17) for lesions less, 75% (12/16) those between 11 20 mm, 14% (1/7) over mm. Complication severe bleeding perforation 22% 5%, respectively. With...
BackgroundNivolumab is approved as an option for third- or later-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) cancer in several countries after ATTRACTION-2. To further improve the therapeutic efficacy first-line therapy, exploration a nivolumab-chemotherapy combination warranted. In part 1 (phase II) ATTRACTION-4, safety and nivolumab combined with S-1 plus oxaliplatin (SOX) capecitabine (CapeOX) therapy unresectable recurrent human epidermal growth factor receptor 2...
This study analyzed outcomes of systemic chemotherapy for advanced neuroendocrine carcinoma (NEC) the digestive system. Clinical data from 258 patients with unresectable or recurrent NEC gastrointestinal tract (GI) hepato-biliary-pancreatic system (HBP), who received chemotherapy, were collected 23 Japanese institutions and retrospectively. Patients had primary sites in esophagus (n = 85), stomach 70), small bowel 6), colorectum 31), hepato-biliary 31) pancreas 31). Median overall survival...
Nivolumab showed improvement in overall survival (OS) ATTRACTION-2, the first phase 3 study patients with gastric/gastroesophageal junction (G/GEJ) cancer treated ≥ 2 chemotherapy regimens. The 2-year follow-up results of ATTRACTION-2 are presented herein.ATTRACTION-2 was a randomized, double-blind, placebo-controlled, trial (49 sites; Japan, South Korea, and Taiwan). median (min-max) period 27.3 (24.1-36.3) months. primary endpoint OS. A subanalysis OS performed based on best response...
The role of maintenance therapy for gastric (GC) or gastroesophageal junction cancer (GEJC) is unclear. We investigated avelumab (anti-programmed death ligand-1 [PD-L1]) after first-line induction chemotherapy GC/GEJC. JAVELIN Gastric 100 was a global, open-label, phase III trial. Eligible patients had untreated, unresectable, human epidermal growth factor receptor 2-negative, locally advanced metastatic GC GEJC. Patients without progressive disease 12 weeks with oxaliplatin plus...
This study evaluated the continuous use of trastuzumab beyond progression (TBP) in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction (G/GEJ) cancer.Patients with HER2-positive G/GEJ cancer refractory to first-line chemotherapy combination fluoropyrimidine and platinum were eligible. Patients randomly assigned paclitaxel (80 mg/m2, days 1, 8, 15, every 4 weeks) (PT; initially 8 mg/kg followed by 6 mg/kg, 3 arms. The primary endpoint was...
Purpose: To assess the long-term toxicity after definitive chemoradiotherapy (CRT) for squamous cell carcinoma (SCC) of esophagus. Patients and Methods: newly diagnosed with SCC esophagus treated CRT between 1992 1999 in our institution were recruited from database on basis following criteria: age ≤ 75 years, performance status (PS; based Eastern Cooperative Oncology Group scale) 0 to 2, clinical tumor-node-metastasis system stage I IVA. The consisted two cycles cisplatin 40 mg/m 2 days 1 8,...
PURPOSE: A phase II study of a combination chemotherapy regimen cisplatin (CDDP) and irinotecan (CPT-11) was conducted to assess its efficacy feasibility in patients with metastatic gastric cancer. PATIENTS AND METHODS: Eligibility criteria included the following: (1) histologically proven cancer measurable lesions, (2) performance status 2 or less, (3) age 75 years younger, (4) one no prior regimens, (5) adequate bone marrow, liver, renal, cardiac functions, (6) written informed consent....